%0 Journal Article
%T Initial evaluation of PET/CT with 18F©\FSU©\880 targeting prostate©\specific membrane antigen in prostate cancer patients
%A Hideo Saji
%A Hiroyuki Kimura
%A Hiroyuki Watanabe
%A Kaori Togashi
%A Kosuke Kitaguchi
%A Masahiro Ono
%A Masao Watanabe
%A Osamu Ogawa
%A Shusuke Akamatsu
%A Takahiro Inoue
%A Takayoshi Ishimori
%A Takayuki Goto
%A Tsuneo Saga
%A Yoichi Shimizu
%A Yuji Nakamoto
%J Archive of "Cancer Science".
%D 2019
%R 10.1111/cas.13911
%X This first©\in©\man study was carried out to evaluate the safety, whole©\body distribution, dose estimation, and lesion accumulation of 18F©\FSU©\880, a newly developed probe targeting prostate©\specific membrane antigen. Six prostate cancer patients with known metastatic lesions underwent serial whole©\body PET/computed tomography (CT) with 18F©\FSU©\880. Blood and urine were analyzed before and after PET/CT. Accumulation of 18F©\FSU©\880 in organs and metastatic lesions in serial PET images were evaluated by measuring the standardized uptake values. From the biodistribution data, the organ doses and whole©\body effective dose were calculated using OLINDA/EXM software was developed by Dr. Michael Stabin of Vanderbilt University, Nashville, Tennessee, USA. 18F©\FSU©\880 PET/CT could be carried out without significant adverse effects. High physiological uptake was observed in the salivary/lachrymal glands and kidneys. The effective dose was calculated to be 0.921 ¡Á 10£¿2 mSv/MBq. Known metastatic lesions were clearly visualized with high image contrast that increased with time, except in 1 patient, whose bone metastases were well©\controlled and inactive. The PET/CT with 18F©\FSU©\880 could be carried out safely and could clearly visualize active metastatic lesions. The present results warrant further clinical studies with a larger number of cases to verify the clinical utility of 18F©\FSU©\880 PET/CT in the management of prostate cancer patients
%K dosimetry
%K fluorine©\18
%K positron emission tomography/computed tomography
%K prostate cancer
%K prostate©\specific membrane antigen
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361557/